Skip to main content
Medicine logoLink to Medicine
. 2019 Jul 19;98(29):e16368. doi: 10.1097/MD.0000000000016368

Acupoint herbal patching for bronchitis

A protocol systematic review of randomized controlled trials

Ji Hee Jun a,b, Kyeong Han Kim c, Eunhye Song b,d, Lin Anga e, Sunju Park b,
PMCID: PMC6708952  PMID: 31335684

Abstract

Background:

Acupoint herbal patching (AHP) is widely used for symptom management in patients with acute and chronic bronchitis. The purpose of this protocol review is to evaluate the safety and efficacy of AHP for the treatment of bronchitis.

Methods and analysis:

This protocol of systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P). The databases searched will include PubMed, Embase, CENTRAL, Web of Science, 3 Korean medical databases (OASIS, Korea Med, and KMBASE), and the Chinese database China National Knowledge Infrastructure (CNKI). Randomized controlled trials (RCTs) or quasi-RCTs using AHP for bronchitis will be considered. The selection of the studies, data abstraction, and validations will be performed independently by 3 researchers.

Conclusion:

The conclusion of the review will provide evidence that AHP is an effective intervention in patients with bronchitis.

Ethics and dissemination:

As individuals were not involved, ethical approval is not required. Findings will be published in a peer-reviewed journal. This systematic review may inform the treatment of bronchitis patients in clinical practice.

Registration:

This systematic review has been registered with the International Prospective Register of Systematic Reviews (PROSPERO). The reference number is CRD42018110380.

Keywords: acupoint herbal patching, bronchitis, meta-analysis, systematic review

1. Introduction

Bronchitis can be defined as a condition in which the mucosal lining of the bronchial tubes is infected, inflamed, and swollen.[1] This condition may be either acute or chronic. Acute bronchitis is a common short-term illness that usually improves within a few days or may last for some weeks, but generally resolves without lasting complications. Contrary to that, chronic bronchitis is a more serious long-term illness that usually lasts for more than 3 and recurs for at least 2 consecutive years.[2,3] People suffering from bronchitis often present with primary symptoms such as cough, production of thick discolored mucus, varying degrees of breathing difficulties, chest discomfort, and sometimes mild fever or chills.[46] Recent studies have shown that the prevalence of bronchitis is increasing worldwide, and the condition is gradually becoming one of the major public health concerns, regardless of age and sex.[715]

Acupoint herbal patching (AHP) is a treatment that prevents diseases by strengthening the immune system through the stimulation of acupuncture points with small quantities of various herbal preparations.[1618] It is a complex therapy as it uses both herbal medicine and acupoints. Herbal patches are applied to acupoints such as BL-13, BL-15, and BL-17 for 4 to 6 hours. The earliest record of AHP goes back to the classic “Prescriptions for Fifty-two Diseases” (Wushi’er Bingfang), where it was listed as a treatment method, and is still widely used today.[19,20] It is a treatment method that prevents diseases that commonly occur in winter by replenishing the energy of summer. AHP is noninvasive, safe, inexpensive, and easy to use, which makes it suitable for children, adolescents, and the elderly.[21,22] The number of patients using AHP has been steadily increasing over recent years in China and Korea.[23] Statistics from China suggest that approximately 100,000 people are treated with AHP every summer, and the number has increased by 13.14% from 2013 to 2014. The Chinese Acupuncture Society and the China Academy of Chinese Medical Sciences have selected more than 10 hospitals in China where research on the clinical efficacy and safety of AHP is in progress.[24]

Animal studies suggest that AHP reduces immunoglobulin E and interleukin 4 serum levels while it increases interferon gamma serum levels and thus supports the treatment of respiratory diseases. In addition, the treatment can improve symptoms associated with pulmonary function disorders by increasing the forced expiratory volume in the 1st, 2nd, and peak expiratory flow.[19]

A report published by the Organization for Economic Cooperation and Development states that the 3 million premature of patients suffering from respiratory diseases due to fine dust is increasing worldwide.[25] Various studies are being conducted to develop effective therapies for bronchitis, and the interest in herbal treatments has continuously grown. Recently, AHP has been reported to be widely used as an effective alternative treatment for respiratory diseases such as asthma and rhinitis.[20,26,27] Most of the articles analyzed selected acupoints and the herbal ingredients of AHP,[19,28,29] or the effect of and satisfaction with AHP.[23,3032] However, there is no critical appraisal of the current evidence for the treatment of bronchitis and no systematic review.[22]

This systematic review aims to summarize and critically evaluate the evidence from clinical trials that have tested the efficacy of AHP as a treatment for bronchitis.

2. Methods

The protocol for this systematic review was prepared according to the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines.[33]

2.1. Inclusion criteria

2.1.1. Types of studies

We will include randomized controlled trials (RCTs) or quasi-RCTs comparing AHP with conventional medicine. Case studies, case series, case-control studies, and reviews will be excluded. There will be no restrictions on the year or language of publication.

2.1.2. Types of participants

Male and female participants of any age with clinically diagnosed acute or chronic bronchitis will be included. Studies will be excluded if the participants had other serious medical conditions such as cancer, liver disease, or kidney disease and so on.

2.1.3. Types of intervention and controls

All types of herbal patching will be included, with no limitations in the number, administration method, dosage, the composition of herbal medicine, detail of acupoint, or duration of treatment. Treatment with AHP for the purpose of this review was defined as the use of a herbal preparation patch that covered acupoints for a certain period of time. Comparators will include usual care, no treatment, or western medicine. We will exclude studies using other types of AHP for comparison, or those using a different baseline therapy.

2.1.4. Types of outcome measures

  • Primary outcome: Treatment effect (the number of patients whose bronchitis symptoms improved)

  • Secondary outcomes:

    • 1.

      Quality of life

    • 2.

      Adverse events

2.2. Search method and strategy

The databases searched will include PubMed, EMBASE, CENTRAL, Web of Science, 3 major Korean medical databases (OASIS, KoreaMed, and KMBASE) and the Chinese database China National Knowledge Infrastructure (CNKI). We will also search Google Scholar. We will use the following search terms: “acupoint herbal patching” AND “clinical trial” AND “bronchitis.” Searches will be conducted in Korean, English, and Chinese. The process of study selection is presented in the adapted PRISMA flow diagram in Figure 1.

Figure 1.

Figure 1

Flow diagram of the randomized controlled trials selection process in this systematic review. The image by Moher et al is available under the CCBY-NC license in the article “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.”

2.3. Data extraction and assessment of the risk of bias

2.3.1. Data extraction

Two authors (JHJ and ES) will independently screen the titles and abstracts of the studies identified. Two authors (JHJ and KHK) will subsequently screen the full-text articles of studies to be potentially included, and then perform data extraction and quality assessment using a predefined data extraction form. In the event of disagreement between these 2 authors that they cannot resolve through discussion, an arbiter (SJP) will be consulted, who will make the final decision.

2.3.2. Assessment of risk of bias

Three authors (JHJ, KHK, and LH) will assess the quality of the methodology of each individual study using the Cochrane Collaboration's Risk of Bias Assessment tool (version 5.3).[34] This tool comprises 7 domains: random sequence generation, allocation concealment, blinding of the participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting, and other sources of bias. The results of the assessment will be assigned to either of the 3 categories: low, high, or unclear risk of bias.

2.4. Data synthesis

All statistical analyses will be conducted using the Review Manager software (RevMan 5.3). Dichotomous data will be presented as the risk ratio with a 95% confidence interval (CI); continuous data will be reported as mean difference with 95% CI. We will use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) software to determine the quality of evidence based on the Cochrane Handbook for Systematic Reviews of Interventions to create a summary of findings table.[35]

2.4.1. Assessment of heterogeneity

Heterogeneity among included studies will be identified using the I2 test. We will use the random effect model for meta-analysis. If a meta-analysis is possible, we will use the I2 statistic to quantify inconsistencies across the included studies. A cut-off point of 50% will be deemed to indicate substantial heterogeneity. Where heterogeneity exists, we will conduct a subgroup analysis.

2.4.2. Subgroup analysis and the investigation of heterogeneity

Where studies and data permit, subgroup analyses will be conducted based on the method of AHP, the composition of herbal medicine applied with the patches, age, duration of treatment, or the type of control intervention.

2.4.3. Assessment of reporting biases

If 10 or more studies are included, we will assess funnel plot asymmetry for publication bias. We will assess small study effects using Egger method.

3. Discussion

Respiratory diseases caused by air pollution are becoming more severe worldwide. The aim of this study was to provide an update on the treatment effect of AHP by acquiring the literature on its clinical studies. In this review, we will search as comprehensive data sources as possible without any language restrictions. Furthermore, this study aims to provide additional information that will facilitate health policies for the prevention and treatment of bronchitis.

Author contributions

Methodology: Kyeong Han Kim, Eunhye Song, Lin Ang.

Project administration: Kyeong Han Kim.

Writing – original draft: Ji Hee Jun.

Writing – review & editing: Sunju Park.

Footnotes

Abbreviations: CIs = confidence intervals, GRADE = grading of recommendations assessment, development and evaluation, MD = mean difference, OECD = organization for economic cooperation and development, PRISMA = preferred reporting items for systematic review and meta-analysis, PRISMA-P = the preferred reporting items for systematic reviews and meta-analyses protocols, RCT = randomized controlled trials, RevMan = review manager software, RR = risk ratio.

This research was supported by the Daejeon University Research Grants (2018).

The authors have no conflicts of interest to disclose.

References

  • [1].Sturm R. Particles in the lungs of patients with chronic bronchitis–part 1: deposition modeling. J Public Health Emerg 2019;5:1–0. [Google Scholar]
  • [2].Committee of Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965;285:775–9. [PubMed] [Google Scholar]
  • [3].Wark P. Bronchitis (acute). BMJ Clin Evid 2015;2015:pii: 1508. [PMC free article] [PubMed] [Google Scholar]
  • [4].Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959;2:257–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Guerra S, Sherrill DL, Venker C, et al. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 2009;64:894–900. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006;129:95S–103S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Cerveri I, Accordini S, Verlato G, et al. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001;18:85–92. [DOI] [PubMed] [Google Scholar]
  • [8].Axelsson M, Ekerljung L, Eriksson J, et al. Chronic bronchitis in West Sweden - a matter of smoking and social class. Eur Clin Respir J 2016;3:30319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Zhang H, Dong L, Kang Y-K, et al. Epidemiology of chronic airway disease: results from a cross-sectional survey in Beijing, China. J Thorac Dis 2018;10:6168–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Lam HT, Ronmark E, Tu’o’ng NV, et al. Increase in asthma and a high prevalence of bronchitis: results from a population study among adults in urban and rural Vietnam. Respir Med 2011;105:177–85. [DOI] [PubMed] [Google Scholar]
  • [11].Mejza F, Gnatiuc L, Buist AS, et al. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. Eur Respir J 2017;50:1–0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Karunanayake CP, Hagen B, Dosman JA, Pahwa P. Prevalence of and risk factors for chronic bronchitis in a canadian population: the canadian community health survey, 2007 to 2008. Can Respir J 2013;20:231–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Huchon GJ, Vergnenègre A, Neukirch F, et al. Chronic bronchitis among French adults: high prevalence and underdiagnosis. Eur Respir J 2002;20:806–12. [DOI] [PubMed] [Google Scholar]
  • [14].Jindal SK, Aggarwal AN, Gupta D, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH). Int J Tuberc Lung Dis 2012;16:1270–7. [DOI] [PubMed] [Google Scholar]
  • [15].Milenković B, Mitić-Milikić M, Rebić P, et al. Asthma and chronic bronchitis symptoms among adult population of Belgrade. Srp Arh Celok Lek 2011;139:149–54. [DOI] [PubMed] [Google Scholar]
  • [16].Chen CJ, Wu Q, Lin D. The hypothesis of meridians and mechanism of acupoint herbal patching therapy. J Fujian College TCM 2006;26:26–9. [Google Scholar]
  • [17].Zhang J, Wu Q, Lin D, et al. The role of four natures of medicine in acupoint sticking therapy [in Chinese, English Abstract]. Chin Acupunct Moxibustion 2006;26:72–4. [PubMed] [Google Scholar]
  • [18].Lorraine W. San fu moxibustion and lung-related disorders. J Chin 2009;89:14–20. [Google Scholar]
  • [19].Zhou F, Yang D, Lu J, et al. Characteristics of clinical studies of summer acupoint herbal patching: a bibliometric analysis. BMC Complement Altern Med 2015;15:381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Zhou F, Liang N, Maier M, et al. Sanfu acupoint herbal patching for stable asthma: a systematic review and meta-analysis of randomised controlled trials. Complement Ther Med 2017;30:40–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Zhou F, Wu HJ, Zhai JP, et al. Who are the users of a traditional Chinese sanfu acupoint herbal patching therapy in China?: a cross-sectional survey. Medicine 2016;95:e5414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Sung HK, Min SY, Kim JH. Clinical trial study about preventing winter diseases through summer prophylactic treatment using acupoint sticking. J Kor Orient Pediat 2010;24:59–74. [Google Scholar]
  • [23].Song JH, Lee JH, Kim YH. A study on effect and satisfaction of acupoint sticking in hottest period of summer. J Kor Orient Pediat 2018;32:1–0. [Google Scholar]
  • [24].Hsu WH, Ho TJ, Huang CY, et al. Chinese medicine acupoint herbal patching for allergic rhinitis: a randomized controlled clinical trial. Am J Chin Med 2010;38:661–73. [DOI] [PubMed] [Google Scholar]
  • [25].OECD. “Air pollution” in Health at a Glance. Publishing O, ed. Paris. Available at: 10.1787/health_glance-2017-23-en. [DOI] [Google Scholar]
  • [26].Lee SH, Chang GT, Zhang X, et al. Acupoint herbal patching for asthma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e2439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Zhou F, Yan LJ, Yang GY, et al. Acupoint herbal patching for allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials. Clin Otolaryngol 2015;40:551–68. [DOI] [PubMed] [Google Scholar]
  • [28].Wen BL, Zhou H, Liu BY, et al. Analysis on acupoint prescription for acupoint sticking therapy of treating winter diseases in summer for preventing and curing chronic cough and asthma [in Chinese]. Zhongguo Zhen Jiu 2010;30:647–52. [PubMed] [Google Scholar]
  • [29].Fang YG, Zhou XZ, Liu BY, et al. A study on the basic drugs and points for point application in summer to treat the diseases with attacks in winter. J Tradit Chin Med 2010;30:180–4. [DOI] [PubMed] [Google Scholar]
  • [30].Lee SH, Kim CY, Chang GT. Pilot research about influential factors and efficacy judgement of acupoint sticking in dog-days. J Kor Orient Pediat 2011;25:72–81. [Google Scholar]
  • [31].Lee SH, Kim CY, Chang GT. Impact on respiratory diseases of acupoint sticking in dog-days. J Kor Orient Pediat 2012;26:1–2. [Google Scholar]
  • [32].Kim HJ, Lee EJ, Lee SH, Chang GT. The study on investigation of advantages and disadvantages of acupoint sticking in dog-days and side effects of acupoint sticking in dog-days. J Kor Orient Pediat 2014;28:96–107. [Google Scholar]
  • [33].Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Green S. Assessing risk of bias in included studies. In: Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1, The Cochrane Collaboration 2008. [Google Scholar]
  • [35].Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401–6. [DOI] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES